The Emerging Markets business continues Lilly’s legacy to deliver innovative medicines that address unmet needs and have a profound impact on people’s lives around the world. Nearly 100 countries – 80 percent of the world’s population – and 6,000 employees make up Lilly’s Emerging Markets business. Major regions and countries among our Emerging Markets include China, Latin America, Middle East, Russia, Turkey, Australia, Africa and Southeast Asia.
What Makes Us Unique
With a well-balanced and diversified portfolio, the Emerging Markets business is driven by a clear strategic focus to achieve strong, sustainable growth with high integrity. The Emerging Markets business area is experiencing underlying growth as Lilly brings much needed medications to these countries. More than 50 potential launches in the next three years – including medicines in therapeutic areas such as oncology and diabetes and others in new areas of focus for Lilly such as autoimmune, pain and neurodegeneration – will bring forth a steady share of global market growth in Emerging Markets.
Lilly’s Emerging Markets business area is committed to making life better by creating meaningful impact with our partners across the globe. This can only be accomplished by understanding what our customers truly value, and by providing extraordinary customer experiences through exceptional leadership and highly engaged employees.